KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other financing activities: 2009-2024

Historic Other financing activities for Biomarin Pharmaceutical (BMRN) over the last 12 years, with Dec 2024 value amounting to -$3.2 million.

  • Biomarin Pharmaceutical's Other financing activities fell 108.89% to -$94,000 in Q4 2024 from the same period last year, while for Dec 2024 it was -$3.2 million, marking a year-over-year decrease of 19.12%. This contributed to the annual value of -$3.2 million for FY2024, which is 38.98% down from last year.
  • As of FY2024, Biomarin Pharmaceutical's Other financing activities stood at -$3.2 million, which was down 38.98% from -$2.3 million recorded in FY2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Other financing activities peaked at -$398,000 during FY2021, and registered a low of -$3.2 million during FY2024.
  • Moreover, its 3-year median value for Other financing activities was -$2.6 million (2022), whereas its average is -$2.7 million.
  • Its Other financing activities has fluctuated over the past 5 years, first crashed by 554.52% in 2022, then grew by 12.25% in 2023.
  • Biomarin Pharmaceutical's Other financing activities (Yearly) stood at -$398,000 in 2021, then tumbled by 554.52% to -$2.6 million in 2022, then grew by 12.25% to -$2.3 million in 2023, then plummeted by 38.98% to -$3.2 million in 2024.